Finance

Lists
Why is SPRY up 2.10%?
Dive Deeper
SPRY:NASDAQ
ARS Pharmaceuticals Inc
$3.89
+2.10%
(+0.080) 1D
$3.85
-1.03% (-0.040)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SPRY...
Open
$3.86
High
$4.00
Low
$3.79
Mkt. cap
391.06M
Avg. vol.
2.08M
Volume
1.30M
52-wk high
$13.15
52-wk low
$2.44
EPS
-$2.01
Beta
0.98
Shares outstanding
100.53M
No. of employees
205
Open
$3.86
High
$4.00
Low
$3.79
Mkt. cap
391.06M
Avg. vol.
2.08M
Volume
1.30M
52-wk high
$13.15
52-wk low
$2.44
EPS
-$2.01
Beta
0.98
Shares outstanding
100.53M
No. of employees
205
News stories
From web sources and news partners
About ARS Pharmaceuticals Inc
CEO-
Employees205
Founded2015
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 3 analysts giving stock ratings to SPRY in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for SPRY in the last 3 months.
Highest
Current $3.89
$20.00 (+414.14%)
Average
$17.33 (+345.50%)
Lowest
$15.00 (+285.60%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$20.00
+414.1%
11/05/2026
Ryan Deschner
Raymond James
Buy
Maintained
$17.00
+337%
11/05/2026
Roanna Ruiz
Leerink Partners
Buy
Maintained
$15.00
+285.6%
09/08/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/14/2026
Carl Byrnes
Northland Securities
Buy
Maintained
$25.00
+542.7%
04/15/2026
Kyle Bauser
Roth MKM
Buy
Reiterated
$30.00
+671.2%
04/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
28.09M
22.68M
33.66M
37.71M
Cost of goods sold
9.60M
10.62M
17.54M
28.36M
Cost of revenue
9.60M
10.62M
17.54M
28.36M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
59.96M
72.20M
77.58M
43.52M
Operating expense
59.96M
72.20M
77.58M
43.52M
Total operating expenses
69.55M
82.83M
95.12M
71.88M
Operating income
-41.46M
-60.14M
-61.46M
-34.17M
Other non operating income
-3.49M
-
-
-
EBT including unusual items
-41.40M
-60.62M
-62.34M
-35.59M
EBT excluding unusual items
-36.88M
-60.62M
-62.34M
-35.59M
Income tax expense
-80.00K
-
-
-
Effective tax rate
0.19%
-
-
-
Other operating expenses
-
-
-
-
Net income
-41.32M
-60.62M
-62.34M
-35.59M
Net profit margin
-147.13%
-267.26%
-185.21%
-94.37%
Earnings per share
-0.42
-0.61
-0.63
-0.36
Interest and investment income
10.67M
1.97M
1.60M
1.14M
Interest expense
-2.60M
-2.44M
-2.48M
-2.55M
Net interest expenses
8.07M
-473.00K
-874.00K
-1.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.05M
-59.75M
-61.05M
-33.76M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps